Gingival response to nicotine polacrilex.

K. J. Silver, D. P. Sachs, Timothy Hottel

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Nicotine polacrilex (Nicorette) is the only medication approved by the Food and Drug Administration for tobacco dependency treatment. It is available only by prescription. This study sought to determine whether this medication produced any adverse gingival effects. Thirty-one patients (91%) used the nicotine polacrilex for at least 1 month and 20 (59%) for 3 months or more. Five (15%) developed small (less than 2 mm), painless, clear, nonhemorrhagic vesicles which resolved immediately when patients were reinstructed to position the medication in different sites in the mouth. There were no changes in gingival color, contour, consistency and texture, tooth mobility, or periodontal pocket depth. Nicotine polacrilex does not appear to have any significant adverse effects on the gingiva even with up to 6 months of daily use.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalJournal of the American Dental Association (1939)
Volume118
Issue number1
DOIs
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Tobacco Use Cessation Products
Tooth Mobility
Periodontal Pocket
Gingiva
United States Food and Drug Administration
Tobacco
Prescriptions
Mouth
Color

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

Cite this

Gingival response to nicotine polacrilex. / Silver, K. J.; Sachs, D. P.; Hottel, Timothy.

In: Journal of the American Dental Association (1939), Vol. 118, No. 1, 01.01.1989, p. 53-56.

Research output: Contribution to journalArticle

Silver, K. J. ; Sachs, D. P. ; Hottel, Timothy. / Gingival response to nicotine polacrilex. In: Journal of the American Dental Association (1939). 1989 ; Vol. 118, No. 1. pp. 53-56.
@article{84c05c0f3da14e0b85fddf1cf3c7702f,
title = "Gingival response to nicotine polacrilex.",
abstract = "Nicotine polacrilex (Nicorette) is the only medication approved by the Food and Drug Administration for tobacco dependency treatment. It is available only by prescription. This study sought to determine whether this medication produced any adverse gingival effects. Thirty-one patients (91{\%}) used the nicotine polacrilex for at least 1 month and 20 (59{\%}) for 3 months or more. Five (15{\%}) developed small (less than 2 mm), painless, clear, nonhemorrhagic vesicles which resolved immediately when patients were reinstructed to position the medication in different sites in the mouth. There were no changes in gingival color, contour, consistency and texture, tooth mobility, or periodontal pocket depth. Nicotine polacrilex does not appear to have any significant adverse effects on the gingiva even with up to 6 months of daily use.",
author = "Silver, {K. J.} and Sachs, {D. P.} and Timothy Hottel",
year = "1989",
month = "1",
day = "1",
doi = "10.14219/jada.archive.1989.0021",
language = "English (US)",
volume = "118",
pages = "53--56",
journal = "Journal of the American Dental Association",
issn = "0002-8177",
publisher = "American Dental Association",
number = "1",

}

TY - JOUR

T1 - Gingival response to nicotine polacrilex.

AU - Silver, K. J.

AU - Sachs, D. P.

AU - Hottel, Timothy

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Nicotine polacrilex (Nicorette) is the only medication approved by the Food and Drug Administration for tobacco dependency treatment. It is available only by prescription. This study sought to determine whether this medication produced any adverse gingival effects. Thirty-one patients (91%) used the nicotine polacrilex for at least 1 month and 20 (59%) for 3 months or more. Five (15%) developed small (less than 2 mm), painless, clear, nonhemorrhagic vesicles which resolved immediately when patients were reinstructed to position the medication in different sites in the mouth. There were no changes in gingival color, contour, consistency and texture, tooth mobility, or periodontal pocket depth. Nicotine polacrilex does not appear to have any significant adverse effects on the gingiva even with up to 6 months of daily use.

AB - Nicotine polacrilex (Nicorette) is the only medication approved by the Food and Drug Administration for tobacco dependency treatment. It is available only by prescription. This study sought to determine whether this medication produced any adverse gingival effects. Thirty-one patients (91%) used the nicotine polacrilex for at least 1 month and 20 (59%) for 3 months or more. Five (15%) developed small (less than 2 mm), painless, clear, nonhemorrhagic vesicles which resolved immediately when patients were reinstructed to position the medication in different sites in the mouth. There were no changes in gingival color, contour, consistency and texture, tooth mobility, or periodontal pocket depth. Nicotine polacrilex does not appear to have any significant adverse effects on the gingiva even with up to 6 months of daily use.

UR - http://www.scopus.com/inward/record.url?scp=0024575319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024575319&partnerID=8YFLogxK

U2 - 10.14219/jada.archive.1989.0021

DO - 10.14219/jada.archive.1989.0021

M3 - Article

VL - 118

SP - 53

EP - 56

JO - Journal of the American Dental Association

JF - Journal of the American Dental Association

SN - 0002-8177

IS - 1

ER -